孕妇早期院外暴露于非甾体抗炎药与早产风险:全国队列研究
结果显示早期暴露显著增加早产风险,且风险随早产严重程度升高,不同NSAIDs间存在差异。
要点
- 孕22周前院外暴露于非选择性NSAIDs与早产风险显著增加相关。
- 极端早产(22-27WG)风险最高,aOR=1.76(95%CI 1.54-2.00)。
- 吲哚美辛暴露者极端早产aOR高达9.33(95%CI 3.75-23.22)。
核心结论
- 孕22周前院外使用非选择性NSAIDs与早产风险增加相关,但不同NSAIDs的关联强度不同。
主要发现
- 非选择性NSAIDs早期暴露与早产风险显著增加相关:极端早产aOR=1.76(95%CI 1.54-2.00),中度早产aOR=1.28(95%CI 1.17-1.40),晚期早产aOR=1.08(95%CI 1.05-1.11),置信区间不重叠。
- 五种NSAIDs与早产风险显著增加相关:酮洛芬、氟比洛芬、萘丁美酮、依托度酸和吲哚美辛。
- 吲哚美辛暴露者早产aOR=1.92(95%CI 1.37-2.70),极端早产aOR=9.33(95%CI 3.75-23.22)。
关键数值与推荐
- 早产定义为37WG前分娩。
- 极端早产对应22-27WG,中度早产对应28-31WG,晚期早产对应32-36WG。
临床怎么用
- 对孕22周前因非产科适应症考虑使用非选择性NSAIDs(尤其吲哚美辛)时,应权衡早产风险。
- 院外处方NSAIDs前宜评估妊娠状态并优先选择风险较低的替代方案。
局限性
- 回顾性队列设计可能受残余混杂影响。
- 仅纳入院外配发药物,未覆盖住院期间用药。
- 未报告具体适应症信息,无法排除适应症混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of preterm birth associated with nonsteroidal anti-inflammatory drugs (NSAIDs), focusing on early exposure in the period from conception to 22 weeks of gestation (WG). DESIGN: National population-based retrospective cohort study. SETTING: The French National Health Insurance Database that includes hospital discharge data and health claims data. POPULATION: Singleton pregnancies (2012-2014) with a live birth occurring after 22WG from women between 15 and 45 years old and insured the year before the first day of gestation and during pregnancy were included. We excluded pregnancies for which anti-inflammatory medications were dispensed after 22WG. METHODS: The association between exposure and risk of preterm birth was evaluated with GEE models, adjusting on a large number of covariables, socio-demographic variables, maternal comorbidities, prescription drugs and pregnancy complications. MAIN OUTCOME MEASURES: Prematurity, defined as a birth that occurred before 37WG. RESULTS: Among our 1 598 330 singleton pregnancies, early exposure to non-selective NSAIDs was associated with a significantly increased risk of preterm birth, regardless of the severity of prematurity: adjusted odds ratio (aOR) = 1.76 (95% CI 1.54-2.00) for extreme prematurity (95% CI 22-27WG), 1.28 (95% CI 1.17-1.40) for moderate prematurity (28-31WG) and 1.08 (95% CI 1.05-1.11) for late prematurity (32-36WG), with non-overlapping confidence intervals. We identified five NSAIDs for which the risk of premature birth was significantly increased: ketoprofen, flurbiprofen, nabumetone, etodolac and indomethacin: for the latter, aOR = 1.92 (95% CI 1.37-2.70) with aOR = 9.33 (95% CI 3.75-23.22) for extreme prematurity. CONCLUSION: Overall, non-selective NSAID use (delivered outside hospitals) during the first 22WG was found to be associated with an increased risk of prematurity. However, the association differs among NSAIDs. TWEETABLE ABSTRACT: French study for which early exposure to non-selective NSAIDs was associated with increased risk of prematurity.
引用
- Quantin C, Yamdjieu Ngadeu C, Cottenet J, et al. Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study. BJOG. 2021. PMID: 33590634. doi:10.1111/1471-0528.16670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。